Federal Register #2026-13144

DEA Notice: Catalent Pharma Solutions Application to Import Schedule I Controlled Substances for Research

This opportunity concerns the Drug Enforcement Administration (DEA) notice about Catalent Pharma Solutions, LLC's application to import Schedule I controlled substances. - Government Buyer: - U.S. Department of Justice, Drug Enforcement Administration (DEA) - OEM/Vendor: - Catalent Pharma Solutions, LLC - Products/Controlled Substances Requested: - Lysergic acid diethylamide (LSD), drug code 7315 - 5-Methoxy-NN-dimethyltryptamine, drug code 7431 - Psilocybin, drug code 7437 - All substances are Schedule I controlled substances - Quantities not specified - Purpose and Requirements: - Substances to be imported as finished dosage unit products - Intended for use in clinical trials, research, and analytical activities - No authorization for import of finished dosage forms for commercial sale (FDA-approved or non-approved) - Registration is limited to the specified activities and substances - Notable Details: - DEA is soliciting public comments and objections regarding this registration - Only Catalent Pharma Solutions, LLC is named as applicant and importer - No other vendors or OEMs are mentioned

Description

Catalent Pharma Solutions, LLC has applied to be registered as an importer of basic classes of controlled substances including Lysergic acid diethylamide, 5-Methoxy-NN-dimethyltryptamine, and Psilocybin. The company plans to import these substances as finished dosage unit products for clinical trials, research, and analytical activities. No other activities for these drug codes are authorized for this registration. Comments on the application must be submitted electronically by July 30, 2026.

View original listing